Scientists at the Indian Institute of Science have revealed the structural details of how the encephalomyocarditis virus (EMCV) commandeers host ribosomes via its IRES. The breakthrough opens new avenues for antiviral drug development.

Key Takeaways

  • Viruses co‑opt host ribosomes for protein synthesis
  • EMCV IRES directly binds the 40S ribosomal subunit and initiator tRNA
  • Targeting IRES could lead to novel therapeutic strategies

Mechanism of Ribosome Hijacking

Researchers at the Indian Institute of Science (IISc) employed cryo‑electron microscopy (cryo‑EM) to visualize the interaction between the encephalomyocarditis virus (EMCV) internal ribosomal entry site (IRES) and the host’s 40S ribosomal subunit. This binding displaces normal host translation and prioritizes viral gene expression.

Using a bespoke pull‑down strategy, a PhD candidate isolated the EMCV‑IRES‑containing pre‑initiation complex from rabbit reticulocyte lysates. The intact complex, including the 40S subunit, initiator tRNA, and eIF2, was then subjected to high‑resolution cryo‑EM analysis.

Historical Background

IRES elements were first identified over two decades ago in EMCV and poliovirus, yet their three‑dimensional architecture remained elusive. Earlier studies only hinted at ribosome recruitment without detailing the precise molecular contacts. IISc’s latest work fills this critical knowledge gap.

Why This Matters

BozokMedia analysis shows that molecules capable of blocking IRES‑ribosome interactions could serve as broad‑spectrum antivirals against not just EMCV but also other IRES‑dependent viruses such as poliovirus, potentially reshaping global infectious‑disease strategies.

"Understanding the IRES‑ribosome interface is a game‑changer for preventing viral infections," says Prof. Tanweer Hussain.
Did You Know?: IRES elements are present in many human pathogens, making them a high‑value target for next‑generation antiviral therapeutics.

Frequently Asked Questions

Q: Are IRES‑targeted drugs currently available?
A: They are still in the research phase, but early pre‑clinical results are promising.

Q: Which diseases could benefit most from this discovery?
A: Primarily neurological and cardiac conditions caused by EMCV, poliovirus and other IRES‑driven viruses.